Schrödinger, Inc.

Executive Summary

Schrödinger, Inc. is a pioneer in computational drug discovery, leveraging its physics-based platform and AI to predict molecular properties and accelerate the identification of novel therapeutics. The company operates a dual business model: licensing its software to pharmaceutical partners and advancing a proprietary pipeline of drug candidates in oncology and immunology. With over three decades of development, Schrödinger's platform is widely recognized for its ability to reduce the time and cost of early-stage drug development, making it a key enabler in the biotech ecosystem. The company's public listing and consistent revenue growth from software sales underscore its commercial viability, while its internal pipeline offers significant upside potential through drug development milestones and eventual product approvals. As the industry increasingly embraces computational methods, Schrödinger is well-positioned to benefit from secular trends toward AI-driven R&D.

Upcoming Catalysts (preview)

• Q2 2026Phase 1 data readout for SGR-1505 (MALT1 inhibitor) in B-cell malignancies60% success
• Q3 2026New strategic partnership or software deal with a top-20 pharma company75% success
• Q4 2026Release of next-generation platform update with enhanced AI capabilities90% success